On-Label Persistence Through 24 Months in Patients With Psoriatic Arthritis Using Guselkumab or Subcutaneous Interleukin-17A Inhibitors

Philip J. Mease,^{1,2} Jessica Walsh,^{3,4} Timothy P. Fitzgerald,⁵ Soumya D. Chakravarty,^{5,6} Bruno Emond,⁷ Vari Wang,⁷ Patrick Lefebvre,⁷ Dominic Pilon,⁷ Linda Hou,⁵ Anthony Todd,⁵ Shikha Singla,⁸ Joseph F. Merola⁹ ¹Rheumatology Research, Providence Swedish Medical Center, Seattle, WA, USA; ³Salt Lake City, UT, USA; ⁴University of Utah Health, Salt Lake City, UT, USA; ⁴University of Utah Health, Salt Lake City, UT, USA; ⁴University of Utah Health, Salt Lake City, UT, USA; ⁵Johnson, Horsham, PA, USA; ⁶Drexel University of Utah Health, Salt Lake City, UT, USA; ⁶Drexel University College of Medicine, Philadelphia, PA, USA; ¹Contersity of Utah Health, Salt Lake City, UT, USA; ⁶Drexel University of Utah Health, Salt Lake City, UT, USA; ¹Contersity of Utah Health, Salt Lake City, UT, USA; ¹Contersity of Utah Health, Salt Lake City, UT, USA; ¹Contersity College of Medicine, Philadelphia, PA, USA; ¹Contersity College of Medicine, Philadelphia, PA, USA; ¹Contersity College of Medicine, Philadelphia, PA, USA; ¹Contersity College of Medicine, PA, USA; ¹Contersity College of Med ⁷Analysis Group, Inc., Montreal, QC, Canada; ⁸Medical College of Wisconsin, Milwaukee, WI, USA; ⁹Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center, Dallas, TX, USA

Background



Guselkumab (GUS), a fully human interleukin (IL)-23 p19-subunit inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of active psoriatic arthritis (PsA) in July 2020

- FDA-approved dosing regimen¹ (on-label): GUS 100 mg at week 0, week 4, then every 8 weeks



A previous claims-based analysis compared on-label persistence for patients (pts) with PsA initiating treatment with on-label GUS or their first subcutaneous (SC) IL-17A inhibitor (IL-17Ai)²

> - Pts receiving GUS were significantly (~2x) more likely to remain persistent through 12 months




Long-term claims data comparing GUS and SC IL-17Ai persistence beyond 12 months provide additional real-world evidence about treatment persistence in routine clinical care that may differ from stringently controlled clinical trial settings

Objectives

This study utilized health plan claims data to compare treatment persistence through 24 months between pts with active PsA newly initiating an on-label GUS dosing regimen and those starting an initial SC IL-17Ai

Results


The GUS and SC IL-17Ai cohorts included 849 and 2,601 pts, respectively



^a1st GUS or SC IL-17Ai claim during intake period (7/14/2020-12/31/2022). ^bThe SC IL-17Ai cohort is defined as pts with an index claim for an SC IL-17Ai (ie, ixekinumab or secukinumab). ^cAssessed during the 12-month baseline period. GUS=Guselkumab; IL-17Ai=Interleukin-17A inhibitor; PsA= Psoriatic arthritis; Pts=Patients; SC=Subcutaneous.

Previously presented at CCR-West 2024; San Diego, CA, USA; September 26–29, 2024.

Methods



tsDMARD=Targeted synthetic DMARD.

7.4.% in the G	iUS cohort and 67.5% in the SC IL-17Ai cohort had received ≥1 b	DMARD at any time k	pefore the index date ^a
le 1 Weight	ed Baseline Demographics and Clinical Characteristics ^b	GUS	SC IL-17Ai
-	eu Dasenne Demographies and Omnear Onaracteristics	(N=849)	(N=2,601)
mographics			
	Age at index date (years), Mean ± SD [median]	49.7 ± 11.0 [50.9]	49.6 ± 11.3 [50.8]
		59.4	59.4
00	Insurance type at index date	70.0	70 5
	Preferred provider organization	78.0	78.5
· · · · · · · · · · · · · · · · · · ·	Health maintenance organization	11.0	11.0
	Other [°] Year of index date	11.0	10.5
	2020	11.6	11.6
	2020	11.6 39.7	39.7
	2021	48.7	48.7
racteristics	2022	40.1	40.1
	Months between latest observed PsA diagnosis and index date,		
	Mean ± SD [median]	1.3 ± 1.6 [0.7]	1.3 ± 1.4 [0.8]
	Quan-CCI, Mean ± SD [median]	0.6 ± 1.3 [0.0]	0.6 ± 1.3 [0.0]
) (Comorbidities		
	Hyperlipidemia	34.8	36.6
	Osteoarthritis	28.7	31.3
	Diabetes	14.3	15.0
70	Peripheral vascular disease	2.7	2.2
	Psoriasis	84.5	84.5
	Smoking	9.9	11.5
lication Use ^d			
	bDMARDs ^e	50.5	50.5
	0	49.5	49.5
F	1 + 5	44.0	43.7
•	≥2	6.6	6.8
	csDMARDs ^f	25.7	27.0
	tsDMARDs ⁹	21.9	21.9
	Corticosteroids	72.5	71.5

Patient Selection

Index date: 1st GUS or SC IL-17Ai claim during intake period (7/14/2020-12/31/2022)^a • PsA pt identification: \geq 2 PsA Dx (ICD-10-CM code L40.5x) \geq 30 days apart within 12 months prior to or on the index date, and ≥ 1 claim for either GUS or first SC IL-17Ai³

• No claims for other conditions for which GUS or IL-17Ai are approved or other potentially

heumatoid arthritis, systemic connective tissue disorders, relapsing polychondritis, unclassified connective tissue disease, hidradenitis suppurativa, inflammatorv bowel disease. uveitis in the 12-month baseline period preceding the index date. Dx=Diagnoses; ICD-10-CM=International Classification of Disease, 10th revision, Clinical Modification; Pts=Patient

Censoring and Imputations

Censoring: On earliest of first off-label claim or last day of index agent supply preceding end of SC IL-17Ai

28 days 56 days 28 days No imputation[°] Based on time to next a No imputation^c ^a28 days if time to next claim <42 days: 56 days if time to next claim 42-70 days: 84 days if time to next claim >70 days: if there is no next claim, days of supply of the previous of the previous days if time to next claim >70 days if there is no next claim. as 56 days if the original value was missing or if this was the second claim; no imputation for claims with day

Statistical Analyses

Baseline demographic and disease characteristics (12 months pre-index): Balanced between the GUS and SC IL-17Ai cohorts using propensity score-weighting overlap weights

• On-label persistence up to 24 months post-index:

- No treatment discontinuation or dose modification relative to US FDA-approved labeling Proportion of pts determined using *weighted* KM curves
- GUS vs SC IL-17Ai cohorts compared using *weighted* Cox proportional hazard models


Days between administrations ^a	GUS	SC IL-17Ai						
Primary analysis								
2x ^{1,4,5}	112 days	56 days						
Sensitivity analyses								
1 x ^{1,4,5}	56 days	28 days						
Fixed gap	112 days	112 days						
Primary analysis was conducted based on 2x the FDA maintenance interval between administration per label after induction. Sensitivity analyses were conducted based on 1x the FDA maintenance interval between administration per label after induction as well as a fixed discontinuation gap of 112 days. FDA=Food and Drug Administration; GUS=Guselkumab; IL-17Ai=Interleukin-17A inhibitor; KM=Kaplan-Meier; SC=Subcutaneous.								

Pts in the GUS vs SC IL-17Ai cohort were significantly (1.5x) more likely to remain persistent GUS was associated with significantly higher on-label persistence vs SC IL-17Ai at each time point assessed (6/12/18/24 months) with on-label treatment through 24 months Table 2. On-Label Persistence Through 24 Months in Weighted GUS and SC IL-17Ai Cohorts^a • % pts with on-label persistence at 24 months: GUS (44.9%) vs SC IL-17Ai (35.0%)

Cox

- Median time to discontinuation: GUS (20.9 months) vs SC IL-17Ai (12.2 months) Sensitivity analyses:
- 1x FDA maintenance gap: HR (95% CI)=1.54 (1.36; 1.75); p<0.001
- Fixed gap (112 days): HR (95% CI)=1.09 (0.94; 1.27); p=0.252

Primary KM Analysis (2x Duration) of On-Label Persistence in Weighted GUS and SC IL-17Ai Cohorts^{a,b}



Discontinuation was defined as having a gap in treatment of more than twice the duration of days of supply for a claim (i.e., 2x56=112 days for guselkumab or 2x28=56 days for IL-17Ai). Patients with dose changes nconsistent with FDA-approved dosing were censored as of the first dose change. °A weighted Cox proportional hazards model was used to compare on-label persistence between cohorts. CI=Confidence interval; FDA=Food and Drug Administration; GUS=Guselkumab; HR=Hazard ratio; IL-17Ai=Interleukin-17A inhibitor; KM=Kaplan-Meier; SC=Subcutaneous.

The set al. 2023: 3:1053-68. ACKNOWLEDGMENTS: Nedical writing support was provided by Kristin L. Leppard, MS, of Johnson under the direction of the authors in accordance with Good Publication Practice guidelines (Ann Intern Med; 2022: Constrained insert): 10:33-68. ACKNOWLEDGMENTS: Nedical writing support was provided by Kristin L. Leppard, MS, of Johnson under the direction of the authors in accordance with Good Publication Practice guidelines (Ann Intern Med; 20:22: Constrained insert): 10:33-68. ACKNOWLEDGMENTS: Nedical writing support was provided by Kristin L. Leppard, MS, of Johnson under the direction of the authors in accordance with Good Publication Practice guidelines (Ann Intern Med; 20:22: Constrained insert): 10:33-68. ACKNOWLEDGMENTS: Nedical writing support was provided by Kristin L. Leppard, MS, of Johnson with Good Publication Practice guidelines (Ann Intern Med; 20:22: Constrained insert): 10:33-68. ACKNOWLEDGMENTS: Nedical writing support was provided by Kristin L. Leppard, MS, of Johnson with Good Publication Practice guidelines (Ann Intern Med; 20:22: Constrained insert): 10:33-68. Acknowle and the authors in accord and the Ei Eilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Amgen, Ei Eilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, and venty; speaker fees from AbbVie, Acelyrin, Amgen, Ei Eilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Acelyrin, Angen, Ei Eilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, and venty; speaker fees from AbbVie, Acelyrin, Amgen, Ei Eilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Acelyrin, Acelyrin, Acelyrin, Acelyrin, Angen, Ei Eilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, and Venty; speaker fees from AbbVie, Acelyrin, Angen, Ei Eilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, and Venty; speaker fees from AbbVie, Acelyrin, Acelyrin, Acelyrin, Acelyrin, Angen, Ei Eilly, Janssen, Novartis, Pfizer, Sun Pharma, UCB, and Venty; speaker fees from AbbVie, Acelyrin, Acelyrin, Acelyrin, Acelyrin, Acelyrin, Acelyrin, Angen, Ei Eilly, Janssen, Novartis, Pfizer, Sun Pharma, UCB, and Venty; speaker fees from AbbVie, Acelyrin, Acelyrin and be strace is a consulting fees from Abb Vie, Eli Lilly, Incyte, Janssen, EO Pharma, Moonlake, Novartis, Pfizer, Sanofi-Regeneron, Sun Pharma, and UCB. JFM: is a consulting from Eli Lilly, Incyte, Janssen, Elo Lilly, Incyte, Janssen, and UCB. JFM: is a consultant and/or investigator for Abb Vie, Eli Lilly, Incyte, Janssen, and UCB. JFM: is a consulting fees from Abb Vie, Eli Lilly, Incyte, Janssen, and UCB. JFM: is a consulting fees from Abb Vie, Sanofi-Regeneron, Sun Pharma, Moonlake, Novartis, Pfizer, Sanofi-Regeneron, Sun Pharma, and UCB. JFM: is a consulting fees from Abb Vie, Eli Lilly, Incyte, Janssen, Elo Lilly, Incyte, Janssen, Elo Pharma, Moonlake, Novartis, Pfizer, Sanofi-Regeneron, Sun Pharma, and UCB. JFM: is a consulting fees from Abb Vie, Janssen, Elo Lilly, Incyte, Janssen, and UCB. JFM: is a consultant and/or investigator for Abb Vie, Eli Lilly, Incyte, Janssen, Elo Lilly, Incyte, Janssen, Elo Lilly, Incyte, Janssen, and UCB. JFM: is a consultant and/or investigator for Abb Vie, Eli Lilly, Incyte, Janssen, Elo Lilly, Incyte, Janssen, Elo Lilly, Incyte, Janssen, and UCB. JFM: is a consultant and or investigator for Abb Vie, Janssen, and UCB. JFM: is a consultant and or investigator for Abb Vie, Eli Lilly, Incyte, Janssen, Elo Lilly, Incyte, Janssen, Elo Lilly, Incyte, Janssen, Elo Lilly, Incyte, Janssen, Elo Lilly, Incyte, Janssen, and UCB. JFM: is a consultant and or investigator for Abb Vie, Eli Lilly, Incyte, Janssen, Elo Lilly, Incyte, Janss





Key Takeaways

First real-world claims data analysis of treatment persistence over 24 months between active PsA pts newly initiated on GUS vs initial SC IL-17Ai per US FDA-approved labeling



Pts in the GUS vs SC IL-17Ai **cohort were significantly (~1.5x)** more likely to remain persistent on treatment through 24 months



Higher long-term on-label persistence may improve disease management outcomes, including functional status and quality of life, in pts with active **PsA initiating GUS⁶**

Primary Analysis	(2x Duration)
-------------------------	---------------

x proportional hazards model ^b	6 months	12 months	18 months	24 months		
s at risk, n (%)°						
GUS (N=849)	440 (51.8)	179 (21.1)	80 (9.5)	26 (3.1)		
C IL-17Ai (N=2,601)	980 (37.7)	460 (17.7)	225 (8.6)	106 (4.1)		
zard ratios (95% CI)	1.75 (1.45; 2.12)	1.50 (1.29; 1.75)	1.53 (1.32; 1.77)	1.49 (1.29; 1.72)		
-square p-value	<0.001	<0.001	<0.001	<0.001		
Persistence, % (95% CI)						
SUS	80.3 (74.8; 84.8)	61.9 (55.4; 67.7)	55.7 (47.8; 62.9)	44.9 (30.2; 58.6)		
CIL-17Ai	68.0 (64.3; 71.4)	50.5 (45.9; 55.0)	41.5 (35.7; 47.1)	35.0 (27.6; 42.6)		
g-rank test p-value	<0.001	<0.001	<0.001	<0.001		

Propensity score weights were used to obtain a balanced sample. Weights were estimated using a multivariable logistic regression model. Baseline covariates included several demographic and clinical characteristics. ^bWeighted Cox proportional hazard models were used to compare risk of discontinuation between the GUS and SC IL-17Ai cohorts. ^oPts at risk of having the event are pts who have not had the event and have not been lost to follow-up at that point in time. CI=Confidence interval; GUS=Guselkumab; IL-17Ai=Interleukin-17A inhibitor; KM=Kaplan-Meier; Pts=Patients; SC=Subcutaneous.

Strengths and Limitations

- Strengths
- A case-finding algorithm validated in US claims data was used to identify pts with PsA³
- Baseline demographic and disease characteristics between the GUS and SC IL-17Ai cohorts were balanced using propensity score-weighting based on overlap weights, minimizing risk of potential confounding due to differences at baseline
- The claims database assessed a large sample of commercially insured PsA pts in the US; results are likely to be highly generalizable to that population

Limitations

- Results may not be generalizable to
- non-commercially insured US pts or pts outside of the US
- Claims data do not ensure treatments are taken as prescribed
- Claims data do not provide treatment effectiveness nor reasons for discontinuation
- Days of supply in pharmacy claims data can be inaccurate due to coverage restrictions. Imputation is a valid approach that is often utilized in claims-based analyses, but may lead to misclassifications